Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
In Phase 3 SURMOUNT trials, Retatrutide achieved unprecedented 24.2% mean weight loss at the 12mg dose over 48 weeks, with 91% of participants achieving 15% body weight reduction
The K + channel K IR 2.1 functions in tandem with proton influx to mediate sour taste transduction
The GLP-1R agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy
Zero processing fees on every method
Caloric Surplus Consuming more calories than the body expends, creating conditions that support tissue growth (both muscle and fat)
Product Introduction Retatrutide CAS 2381089-83-2 is a new type of multi-receptor agonist that targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and GCGR (glucagon receptor)
US$ 23.74
US$ 21.55
US$ 23.43
US$ 28.05
US$ 29.65
US$ 22.52
US$ 21.83
